BUX — BioMark Diagnostics Balance Sheet
0.000.00%
Last trade - 00:00- CA$52.18m
- CA$52.66m
- CA$0.06m
Annual balance sheet for BioMark Diagnostics, fiscal year end - March 31st, CAD millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 0.383 | 0.072 | 0.157 | 2.48 | 1.01 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.082 | 0.034 | 0.043 | 0.161 | 0.05 |
| Prepaid Expenses | |||||
| Total Current Assets | 0.499 | 0.126 | 0.2 | 2.64 | 1.08 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.969 | 0.589 | 0.852 | 0.454 | 0.723 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 1.47 | 0.732 | 1.09 | 3.13 | 1.86 |
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.5 | 1.66 | 1.24 | 1.23 | 1.1 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 2.11 | 1.88 | 1.7 | 1.39 | 1.53 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -0.636 | -1.15 | -0.61 | 1.74 | 0.331 |
| Total Liabilities & Shareholders' Equity | 1.47 | 0.732 | 1.09 | 3.13 | 1.86 |
| Total Common Shares Outstanding |